Mark Boaz
About
Mark Boaz is a scholar working on Infectious Diseases, Public Health, Environmental and Occupational Health and Virology.
According to data from OpenAlex, Mark Boaz has authored 22 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 17 papers in Public Health, Environmental and Occupational Health and 4 papers in Virology. Recurrent topics in Mark Boaz's work include Mosquito-borne diseases and control (17 papers), Viral Infections and Vectors (16 papers) and Viral Infections and Outbreaks Research (9 papers). Mark Boaz is often cited by papers focused on Mosquito-borne diseases and control (17 papers), Viral Infections and Vectors (16 papers) and Viral Infections and Outbreaks Research (9 papers). Mark Boaz collaborates with scholars based in United States, France and Thailand. Mark Boaz's co-authors include Annapurna Vyakarnam, Philippa Easterbrook, Anele Waters, Shahed Murad, Alain Bouckenooghe, Emmanuel Feroldi, Chitsanu Pancharoen, Manoj Kumar Thakur, Gustavo H. Dayan and Sophia Gailhardou and has published in prestigious journals such as SHILAP Revista de lepidopterología, The Journal of Immunology and The Journal of Infectious Diseases.
In The Last Decade
Mark Boaz
22 papers receiving 672 citations
Peers
Mark Boaz
Ada M. B. Alves Brazil
Fabrizio Carletti Italy
Christian Van Hoecke United States
Chien-Hsiung Pan Taiwan
Timothy Burgess United States
Svenja Weiß United States
Sandra Medina-Moreno United States
Jariyanart Gaywee Thailand
Laura Valentine United States
Citations per year, relative to Mark Boaz Mark Boaz (= 1×)
peers
Ada M. B. Alves
Countries citing papers authored by Mark Boaz
Since
Specialization
Citations
This map shows the geographic impact of Mark Boaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Boaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Boaz more than expected).
Fields of papers citing papers by Mark Boaz
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark Boaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Boaz. The network helps show where Mark Boaz may publish in the future.
Co-authorship network of co-authors of Mark Boaz
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Boaz. A scholar is included among the top collaborators of Mark Boaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Boaz. Mark Boaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Kirstein, Judith L., et al.. (2018). Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults. BMC Infectious Diseases. 18(1). 475–475.
2.
Chokephaibulkit, Kulkanya, Chukiat Sirivichayakul, Usa Thisyakorn, et al.. (2016). Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children. Vaccine. 34(46). 5664–5669.
3.
Plennevaux, Eric, Arunee Sabchareon, Kriengsak Limkittikul, et al.. (2016). Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction. Vaccine. 34(24). 2707–2712.
4.
Feroldi, Emmanuel, Mark Boaz, Sutee Yoksan, et al.. (2016). Persistence of Wild-Type Japanese Encephalitis Virus Strains Cross-Neutralization Five Years following JE-CV Immunization. The Journal of Infectious Diseases. 215(2). jiw533–jiw533.
5.
Torresi, Joseph, Leon Heron, Ming Qiao, et al.. (2015). Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: A randomised study. Vaccine. 33(39). 5127–5134.
6.
Byers, Anthony M., Kelly Haupfear, Tatyana M. Timiryasova, et al.. (2015). Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine. Open Forum Infectious Diseases. 2(4). ofv172–ofv172.
7.
Feroldi, Emmanuel, Chitsanu Pancharoen, Pope Kosalaraksa, et al.. (2014). Primary Immunization of Infants and Toddlers in Thailand with Japanese Encephalitis Chimeric Virus Vaccine in Comparison with SA14-14-2. The Pediatric Infectious Disease Journal. 33(6). 643–649.
8.
Huang, Li‐Min, Tzou‐Yien Lin, Cheng‐Hsun Chiu, et al.. (2014). Concomitant administration of live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) and measles, mumps, rubella (MMR) vaccine: Randomized study in toddlers in Taiwan. Vaccine. 32(41). 5363–5369.
9.
Kim, Dong Soo, Gwang Cheon Jang, Sung Ho, et al.. (2014). A randomized study of the immunogenicity and safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in comparison with SA14-14-2 Vaccine in children in the Republic of Korea. Human Vaccines & Immunotherapeutics. 10(9). 2656–2663.
10.
Bonaparte, Matthew, Emmanuel Feroldi, Claude Méric, et al.. (2014). Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India. BMC Infectious Diseases. 14(1). 156–156.
11.
Boaz, Mark, et al.. (2014). Virological confirmation of suspected dengue in a Phase 2 Latin American vaccine trial: Implications for vaccine efficacy evaluation. 3. 127–133.
12.
Villar, Luis, Doris Maribel Rivera-Medina, José Luis Arredondo-Garcı́a, et al.. (2013). Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds. The Pediatric Infectious Disease Journal. 32(10). 1102–1109.
13.
Dayan, Gustavo H., et al.. (2013). Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine. 31(44). 5047–5054.
14.
Feroldi, Emmanuel, María Rosario Capeding, Mark Boaz, et al.. (2013). Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Human Vaccines & Immunotherapeutics. 9(4). 889–897.
15.
Feroldi, Emmanuel, Chitsanu Pancharoen, Pope Kosalaraksa, et al.. (2012). Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: Randomized, controlled phase 3 immunogenicity and safety trial. Human Vaccines & Immunotherapeutics. 8(7). 929–937.
16.
Chokephaibulkit, Kulkanya, Chukiat Sirivichayakul, Usa Thisyakorn, et al.. (2010). Safety and Immunogenicity of a Single Administration of Live-attenuated Japanese Encephalitis Vaccine in Previously Primed 2- to 5-year-olds and Naive 12- to 24-month-olds. The Pediatric Infectious Disease Journal. 29(12). 1111–1117.
17.
Kotton, Camille N., Alexander Lankowski, Li-Mei Chen, et al.. (2006). Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine. 24(37-39). 6216–6224.
18.
Boaz, Mark, et al.. (2003). CD4 responses to conserved HIV-1 T helper epitopes show both negative and positive associations with virus load in chronically infected subjects. Clinical & Experimental Immunology. 134(3). 454–463.
19.
King, Deborah, et al.. (2003). Evidence for Gag p24-specific CD4 T cells with reduced susceptibility to R5 HIV-1 infection in a UK cohort of HIV-exposed-seronegative subjects. AIDS. 17(16). 2299–2311.
20.
Boaz, Mark, Anele Waters, Shahed Murad, Philippa Easterbrook, & Annapurna Vyakarnam. (2002). Presence of HIV-1 Gag-Specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T Cell Responses Is Associated with Nonprogression in HIV-1 Infection. The Journal of Immunology. 169(11). 6376–6385.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ada M. B. Alves Breakdown of academic impact, for papers by Fabrizio Carletti Breakdown of academic impact, for papers by Angélique Ndjoyi‐Mbiguino Breakdown of academic impact, for papers by Christian Van Hoecke Breakdown of academic impact, for papers by Chien-Hsiung Pan Breakdown of academic impact, for papers by Timothy Burgess Breakdown of academic impact, for papers by Svenja Weiß Breakdown of academic impact, for papers by Sandra Medina-Moreno Breakdown of academic impact, for papers by Jariyanart Gaywee Breakdown of academic impact, for papers by Laura Valentine